Revenue, 2025

USD 268.39 Billion

Forecast, 2035

USD 587.74 Billion

CAGR, 2026-2035

9.1%

Report Coverage

Global

Drug Delivery CDMO Services Market Trends for 2026

The global drug delivery CDMO services market size was estimated at USD 246 billion in 2025 and is predicted to increase from USD 268.39 billion in 2026 to approximately USD 587.74 billion by 2035, expanding at a CAGR of 9.1% from 2026 to 2035. Increasing demand for advanced treatment options is increasing the use of drug delivery CDMO services. Growing regulatory complexities, expanding drug delivery technologies, increasing collaborations, and new product launches are enhancing the market growth.

Key Takeaways

• Drug delivery CDMO services market to crossed USD 268.39 billion by 2026.
• Market projected at USD 587.74 billion by 2035.
• CAGR of 9.1% expected in between 2026 to 2035.
• North America held the major revenue share of 40% in the global drug delivery CDMO services market in 2025.
• Asia Pacific held 20% share of the market in 2025 and is expected to grow at the fastest CAGR during the forecast period.
• By service type, the manufacturing services segment held a dominant revenue share of 45% of the market in 2025.
• By service type, the development services segment held 40% of market share in 2025 and is expected to grow at the fastest CAGR of 10% during the forecast period.
• By drug type, the small molecule drugs segment held a dominant revenue share of 55% of the market in 2025.
• By drug type, the gene and cell therapy products sub-segment held 10% of market share in 2025 and is expected to grow at the fastest CAGR during the forecast period.
• By end-user, the pharmaceutical companies segment held a dominant position in the market with a share of 60% in 2025.
• By end-user, the emerging biotech sub-segment held 20% of the market in 2025 and is expected to grow at the fastest CAGR during the forecast period.
• By technology type, the polymeric systems segment held a dominant revenue share of 30% of the drug delivery CDMO services market in 2025.
• By technology type, the microneedles segment held 25% of market share in 2025 and is expected to grow at the fastest CAGR during the forecast period.

What are the Drug Delivery CDMO Services?

The drug delivery CDMO services market is driven by the increasing complexity of modern therapeutics and increasing outsourcing trends. The drug delivery CDMO services encompass the specialized services promoting the development, manufacturing, and optimization of the drug delivery system. The help in the development of advanced drug delivery systems, new dosage forms, complex formulations, and supports commercial manufacturing and clinical trials with regulatory compliance.

What are the Applications of AI in the Market?

 AI offers a wide range of applications in the drug delivery CDMO services market, promoting formulation and process optimization. It also offers drug release modelling and predictive analytics, which help in the development of stable and effective formulations. AI is also used for quality control, large-scale production, development of patient-specific formulations, and regulatory compliance, promoting faster and optimized production.

What are the Trends & Future Outlook of the Market?

Growing Outsourcing Trends

A rise in the demand for integrated end-to-end CDMO services is increasing the outsourcing trends, promoting new collaborations. This is driving the outsourcing of various products to leverage their development, manufacturing, and packaging services.

Rise Of Advanced Therapies

The growing adoption of advanced treatment options like gene therapies, biologics, antibody drug conjugates, and mRNA therapy is increasing the innovations. This is promoting the use of drug delivery CDMO services. They offer new technologies like nanoparticles and lipid-based drug delivery systems, encouraging their adoption.

Technological Advancements

The growing technological innovations are driving the development of new drug development and manufacturing solutions. AI-powered formulation development, smart delivery devices, single-use systems, continuous manufacturing, on-body injectors, and modular facilities are being developed.

Executive Summary Table

Segmental Insights

By Service Type Insights

The Manufacturing Services Segment Dominated the Market With 45% in 2025

The manufacturing services segment led the drug delivery CDMO services market with 45% share in 2025, due to growth in the demand for commercial-scale manufacturing. A rise in the demand for affordable large-scale production also increased their use. The growth in the demand for generics and biologics has also increased their use.

The development services segment led the market with 40% share in 2025, and is expected to achieve the highest CAGR of 10% during the forecast period due to high large-scale production rates. The growth in the approval rates also increased their demand for commercial-scale manufacturing. Their established infrastructure, regulatory expertise, and advanced technologies are also increasing their use for the manufacturing of complex formulations.

The packaging services segment held 10% of the drug delivery CDMO services market share in 2025, driven by growing regulatory pressure on packaging standards. Growing temperature-sensitive products are also increasing the demand for these services. Growing technological innovations are also increasing their advantages.

The others (e.g., regulatory affairs) segment is expected to grow significantly in the market share in 2025, due to growing regulatory complexities. The increasing development of new drug products is also increasing their use for faster approvals. Frequent guideline updates also promote their use.

By Drug Type Insights

The Small Molecule Drugs Segment Dominated the Market With 55% in 2025

The small molecule drugs segment accounted for the highest revenue share of 55% of the drug delivery CDMO services market in 2025, due to the presence of large volumes of small molecule therapies and treatment options. Their cost-effective manufacturing and development also increased the use of drug delivery CDMO services. The growth in the demand for generic products also increased their use.

The biologics segment held the second-largest share of 35% of market share in 2025, due to rapid advancements in biotechnology and gene therapy. Growing chronic disease burden and patent expiration are also increasing the use of drug delivery CDMO services. Their advanced technologies and expertise are also increasing their adoption.

The gene and cell therapy products sub-segment held 10% of the market share in 2025 and is expected to show the highest CAGR growth during the forecast period, due to a surge in cell-based therapies for rare diseases. Increasing incidences of cancer and rare diseases are also increasing their demand. This is driving the use of CDMO services for the development of new therapies.

The others (e.g., biosimilars) segment held 10% of the drug delivery CDMO services market share in 2025, due to growing focus on developing new biosimilars. Growing government support is also encouraging the use of drug delivery CDMO services. Increasing approvals and demand for cancer therapeutics are also increasing their use.

By End-User Insights

The Pharmaceutical Companies Segment Dominated the Market With 60% in 2025

The pharmaceutical companies segment contributed the biggest revenue share of 60% of the drug delivery CDMO services market in 2025, due to the extensive use of CDMO for drug development and production. The presence of complex drug portfolios also increased their use. The growth in the development of new drugs and biologics has also increased their use.

The biotechnology companies segment held the second-largest share of 35% of the market in 2025, due to the rising number of biotech companies using contract manufacturing. Increasing demand for biologics and oncology treatments is also increasing the collaboration with CDMOs. Rising precision medicine demand is also increasing its use.

The emerging biotech sub-segment held 20% of the market share in 2025 and is expected to expand with the highest CAGR during the forecast period, due to increasing funding and research for novel therapies. Growing chronic disease burden and high unmet needs are also increasing the development of new products, driving the demand for CDMO services. Their advanced technologies are also attracting companies.

The others (e.g., contract research organizations) segment held 5% of the drug delivery CDMO services market share in 2025, driven by their rapid expansion. Increasing outsourcing trends are also promoting their use. Expanding clinical trials are also increasing the use of drug delivery CDMO services.

By Technology Insights

The Polymeric Systems Segment Dominated the Market With 30% in 2025

The polymeric systems segment held the largest revenue share of 30% of the drug delivery CDMO services market in 2025, due to high demand for drug release-controlled delivery. Their high compatibility and improved stability also increased their use, which promoted the adoption of drug delivery CDMO services. Their affordable and targeted delivery capabilities also increased their use.

The microneedles segment held the second-largest share of 25% of the market in 2025 and is expected to grow with the fastest CAGR during the forecast period, due to growing demand for painless and efficient drug delivery. Increasing shift towards minimally invasive delivery is also increasing their use. Additionally, growing self-administration trends are also driving their demand.

The liposome technologies segment held 20% of the market share in 2025, due to its use in improving the bioavailability of drugs. They also help in enhancing the biocompatibility and stability of the formulations. Their growing applications in oncology and vaccine development are also increasing their demand.

The others (e.g., transdermal patches) segment held 25% of the drug delivery CDMO services market share in 2025, due to growing demand for non-invasive delivery. Their fewer side effects and sustained release profile are also increasing their use. This, in turn, is driving the adoption of drug delivery CDMO services.

Regional Insights

Strong Regulatory Support Drives North America

North America dominated the drug delivery CDMO services market with 40% in 2025, due to strong regulatory support for drug development and manufacturing. The presence of robust pharmaceutical industries and R&D infrastructure also increased the use of drug delivery CDMO services.  The growth in outsourcing trends also contributed to the market growth.

U.S. Market Trends

A rise in pharmaceutical outsourcing across the U.S. is increasing the use of drug delivery CDMO services. The presence of robust industries and high R&D investments is also promoting innovations, driving their demand. The increasing demand for advanced therapies and drug delivery technologies is also increasing their use.

Expanding Pharmaceutical Manufacturing Boosts the Asia Pacific

Asia Pacific held 20% share of the drug delivery CDMO services market in 2025 and is expected to grow at the fastest CAGR during the forecast period, due to rapid expansion in pharmaceutical manufacturing. The growing chronic disease burden is also increasing the use of drug delivery CDMO services for new drug formulations. Expanding clinical trials are also enhancing the market growth.

India Market Trends

The expanding pharmaceutical and CDMO infrastructure in India is increasing the use of drug delivery CDMO services. Expanding generic drug manufacturing and outsourcing trends are also increasing their demand. Their affordable services and expertise are also promoting their adoption rates.

Market Value Chain Analysis

R&D

• The R&D of the drug delivery CDMO services focuses on the development of automated biomanufacturing and next-generation bioavailability.
• Key players: Lonza and Evonik.

Packaging and Serialization

• The packaging and serialization of the drug delivery CDMO services involve the use of automated secondary packing along with the track-and-trace technology.
• Key players: Vetter Pharma, Sharp Service, and Recipharm.

Patient Support and Services

• The patient-centric device design, training devices, and onboarding solutions are provided in the patient support and services of the drug delivery CDMO services.
• Key players: Aptar Pharma, West Pharmaceutical Services.

Who are the Market Top Vendors and What are Their Offerings?

SWOT Analysis

Strengths

• The drug delivery CDMO services offer specialized expertise, which increases their adoption rates.
• They also offer end-to-end and affordable solutions that increase their use.
• They accelerate the development timeline and promote large-scale production, driving their use.
• Presence of advanced technologies and regulatory support also increases their use.

Weaknesses

• Dependency on clients acts as the major weakness in the drug delivery CDMO services market, which limits their use.
• Shortage of skilled personnel and regulatory burden also limit their use.

Opportunities

• A rise in chronic diseases is increasing the demand for effective treatment options, increasing the use of drug delivery CDMO services.
• Increasing outsourcing trends and expanding demand for complex formulations are increasing the use of drug delivery CDMO services.
• Growing adoption of biologics and biosimilars is also increasing their adoption rates.
• Expanding demand for personalized medicine is also promoting its use.

Threats

• Intense competition and high operational costs limit the use of drug delivery CDMO services.
• Rapidly evolving technologies and regulatory standards also slow down their development and manufacturing process and delay their approvals.

Recent Developments in the Market

• In April 2026, tentative approval from the U.S. FDA for an Abbreviated New Drug Application (ANDA) for a generic version of Ozempic semaglutide injection was announced by the collaboration between OneSource Specialty Pharma, Orbicular Pharmaceutical Technologies, and a U.S.-based front-end partner. In this collaboration, OneSource will act as the contract development and manufacturing organisation partner (CDMO).
• In February 2026, successful participation in Vitafoods India 2026, which is the country's premier nutraceutical and wellness exhibition, was announced by Avery Pharmaceuticals Pvt. Ltd. The company will exhibit its contract manufacturing development services for orally dissolving strips and cutting-edge solutions in drug delivery.

Segments Covered in the Report

By Service Type

• Development Services
  • Formulation Development
  • Analytical Testing
  • Process Development
• Manufacturing Services
  • Commercial Manufacturing
  • Clinical Manufacturing
  • Fill and Finish Services
• Packaging Services
  • Primary Packaging
  • Secondary Packaging
• Others (e.g., Regulatory Affairs)

By Drug Type

• Small Molecule Drugs
  • Oral Solid Dosage Forms
  • Injectable Dosage Forms
  • Topical Drugs
• Biologics
  • Monoclonal Antibodies
  • Vaccines
  • Gene and Cell Therapy Products
• Others (e.g., Biosimilars)

By End-user

• Pharmaceutical Companies
  • Innovator Companies
  • Generic Companies
• Biotechnology Companies
  • Emerging Biotech
  • Established Biotech
• Others (e.g., Contract Research Organizations)

By Technology

• Liposome Technologies
  • Liposomal Drug Delivery
  • Nanoparticle-based Delivery
• Polymeric Systems
  • Hydrogels
  • Micelles
• Microneedles
• Others (e.g., Transdermal Patches)

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA